Foresee Pharmaceuticals Receives China NMPA Approval for Prostate Cancer Drug CAMCEVI®
China's National Medical Products Administration (NMPA) has approved CAMCEVI® 42 mg for the treatment of advanced prostate cancer. Changchun GeneScience Pharmaceutical will commercialize the drug in China.
Taipei, Taiwan – Foresee Pharmaceuticals announced that its licensing partner, Changchun GeneScience Pharmaceutical (GenSci), has received approval from China's National Medical Products Administration (NMPA) for CAMCEVI® 42 mg. The drug is indicated for adult patients with advanced prostate cancer.
CAMCEVI® 42 mg is a ready-to-use, six-month subcutaneous depot formulation of leuprolide mesylate. GenSci holds exclusive rights to commercialize CAMCEVI® in China across all current and pipeline indications, including advanced prostate cancer, central precocious puberty, and premenopausal breast cancer.
Dr. Ben Chien, Chairman and CEO of Foresee Pharmaceuticals, stated, "We are pleased that our partner GenSci will be launching CAMCEVI® 42 mg in China. These efforts will significantly contribute to the growth of our global CAMCEVI® franchise."
The drug is already approved for advanced prostate cancer in the United States, the European Union, and other markets. GenSci has also submitted a supplemental new drug application to the NMPA for leuprolide mesylate injectable emulsion for the additional indication of premenopausal breast cancer, which is currently under review.